Adaptive Survival Analysis
Adaptive survival analysis integrates adaptive clinical trial design with time-to-event statistical methods, allowing pre-specified modifications to sample size, event targets, or allocation ratios at interim stages based on accumulating survival data. It is widely used in oncology, cardiovascular, and infectious disease research where the primary endpoint is a hazard-based outcome such as progression-free survival or all-cause mortality.
Rekodi ya chanzo
Nukuu zimehamishwa kwa uhalisi kutoka kwa rekodi ya chanzo cha mbinu. Hakuna uthibitisho wa kiwango cha dai unaodokezwa kutoka kwao.
- Bauer, P., & Posch, M. (2004). Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections. Statistics in Medicine, 23(8), 1333–1353. · URL
- Mehta, C., Bhatt, M., & Bhattacharya, R. (2009). Adaptive randomization for survival endpoints in oncology trials. Journal of Clinical Oncology, 27(15_suppl), e20750. · URL
Madai yaliyotunzwa
Madai yamehifadhiwa katika daftari la ushahidi, kila moja ikiwa na tathmini yake.
Mwonekano huu haubuni tathmini ya dai wakati daftari haina yoyote.
Mbinu zinazohusiana
Zilizotengenezwa kutoka kwa grafu ya mbinu na kuonyeshwa kama uhusiano uliopendekezwa na mashine — hakuna dai la ushahidi linalodokezwa.